A Perspective on the Toxicological Mechanisms Possibly Contributing to the Failure of Oral Glycoprotein IIb/IIIa Antagonists in the Clinic

Author： Sherwin K.B. Sy Aaron L. Levenstadt

Publisher： Adis International

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.4, Iss.1, 2004-01, pp. : 1-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oral glycoprotein IIb/IIIa antagonists unsuccessful

Inpharma, Vol. 1, Iss. 1345, 2002-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Platelet glycoprotein IIb/IIIa receptor antagonists

By Casserly I.P. Moliterno D.J.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 3, 2000-03 ,pp. : 419-433

Informa Healthcare

Access to resources Recommend Favorite

Current Issues with Glycoprotein IIb-IIIa Antagonists

Current Drug Targets, Vol. 12, Iss. 12, 2011-11 ,pp. : 1813-1820

Bentham Science Publishers

Access to resources Recommend Favorite

Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker

By Liu F. Craft R.M. Morris S.A. Carroll R.C.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 11, 2000-11 ,pp. : 2673-2687

Informa Healthcare

Access to resources Recommend Favorite

Potential Role of Platelet Glycoprotein IIb/IIIa Antagonists in Cerebrovascular Disorders

By Mousa S.A.

CNS Drugs, Vol. 13, Iss. 3, 2000-03 ,pp. : 155-160

Adis International

Access to resources Recommend Favorite